About Us

MediciNova, Inc. is a development-stage biopharmaceutical company focused on acquiring, developing and commercializing high-quality small molecule therapeutics. Through strategic alliances primarily with Japanese pharmaceutical companies, MediciNova has built a diversified portfolio of drug candidates each of which we believe has broad patent protection, a well-characterized and differentiated therapeutic profile and attractive commercial potential. MediciNova currently has eight compounds, six in clinical development, for ten different therapeutic indications representing significant market opportunities. MediciNova’s pipeline includes potential treatments for multiple sclerosis, status asthmaticus, asthma, interstitial cystitis, cancer, Generalized Anxiety Disorder, insomnia, preterm labor, urinary incontinence and thrombotic disorders. MediciNova’s strategy is to advance its clinical programs through at least the Phase II proof-of-concept stage and, at appropriate points of high-value inflection, to establish strategic alliances and partnerships to support Phase III clinical testing and commercialization of selected development programs. MediciNova may also retain certain of these promising compounds for further in-house development and potential commercialization in the U.S; MediciNova is currently focusing its resources on MN-166 (multiple sclerosis) and MN-221 (for status asthmaticus) for that purpose. MediciNova’s executive management team has extensive global development, regulatory and commercial experience, and manages its international clinical and manufacturing operations through efficient and cost-effective utilization of contract research organizations. Headquartered in San Diego, California, MediciNova today has approximately 25 employees.